|Bid||95.82 x 100|
|Ask||141.00 x 200|
|Day's Range||145.85 - 148.35|
|52 Week Range||95.80 - 163.75|
|PE Ratio (TTM)||22.06|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||184.63|
DUBLIN, Aug. 17, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of $500 million aggregate principal amount of exchangeable senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer has also granted the initial purchasers a 13-day option to purchase up to an additional $75 million aggregate principal amount of notes. Jazz Pharmaceuticals plc intends to use the net proceeds from this offering to repay all or a substantial portion of $500 million of outstanding borrowings under its revolving credit facility. Any remaining net proceeds will be used for general corporate purposes, including potential business development activities.
Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 15, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Illumina, Inc. (NASDAQ: ILMN ), ...
Q2 2017 Jazz Pharmaceuticals PLC Earnings Call